Compare CVNA & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVNA | NTRA |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3B | 45.3B |
| IPO Year | 2017 | 2015 |
| Metric | CVNA | NTRA |
|---|---|---|
| Price | $73.94 | $338.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 15 |
| Target Price | ★ $439.67 | $259.07 |
| AVG Volume (30 Days) | ★ 9.3M | 1.4M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 431.45 | 0.65 |
| EPS | ★ 8.45 | N/A |
| Revenue | ★ $20,322,000,000.00 | $210,939,000.00 |
| Revenue This Year | $34.66 | $18.08 |
| Revenue Next Year | $23.38 | $19.65 |
| P/E Ratio | $8.96 | ★ N/A |
| Revenue Growth | ★ 48.63 | N/A |
| 52 Week Low | $56.12 | $157.43 |
| 52 Week High | $486.89 | $337.12 |
| Indicator | CVNA | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.01 | 72.33 |
| Support Level | $62.23 | $187.64 |
| Resistance Level | $418.77 | N/A |
| Average True Range (ATR) | 3.44 | 10.88 |
| MACD | 0.86 | 1.95 |
| Stochastic Oscillator | 96.84 | 100.00 |
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.